Sharath Kumar

Systemic Lupus Erythematosus

Multifunctional nanoparticle-mediated combining therapy for human diseases

Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real‐world clinical experience from India

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial